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Summary 
The development of type I diabetes in the nonobese diabetic (NOD) mouse is under the control 
of multiple genes, one or more of which is linked to the major histocompatibility complex (MHC). 
The MHC class II region has been implicated in disease development, with expression of an 
I-E transgene in NOD mice shown to provide protection from insulitis and diabetes.  To examine 
the effect of expressing an I-E + or I-E-  non-NOD  MHC  on the NOD background, three 
I-E + and three I-E- NOD MHC congenic strains (NOD.H-2/s,  NOD.H-2  k, and NOD.H-2  h2, 
and NOD.H-2 h4, NOD.H-2/7,  and NOD.H-2 b, respectively) were developed. Of these strains, 
both I-E + NOD.H-2 h2 and I-E-  NOD.H-2 h4 mice developed insulitis, but not diabetes.  The 
remaining four congenic strains were free of insulitis and diabetes.  These results indicate that 
in the absence of the NOD MHC, diabetes fails to develop.  Each NOD MHC congenic strain 
was crossed with the NOD strain to produce I-E + and I-E- F1 mice; these mice thus expressed 
one dose of the NOD MHC and one dose of a non-NOD MHC on the NOD background. 
While a single dose of a non-NOD MHC provided a large degree of disease protection to all 
of the F1 strains,  a proportion of I-E + and I-E-  F1 mice aged 5-12 mo developed insulitis and 
cyclophosphamide-induced diabetes.  When  I-E +  F1  mice were aged 9-17  mo,  spontaneous 
diabetes developed as well. These data are the first to demonstrate that I-E + NOD mice develop 
diabetes, indicating that expression of I-E in NOD  mice is not in itself sufficient to prevent 
insulitis or diabetes.  In fact, I-E-  F1 strains were no more protected from diabetes than I-E + 
F1 strains, suggesting that other non-NOD MHC-linked genes are important in protection from 
disease. Finally, transfer of NOD bone marrow into irradiated I-E + F1 recipients resulted in high 
incidences of diabetes,  indicating that expression of non-NOD MHC products in the thymus, 
in the absence of expression in bone marrow-derived ceils, is not sufficient to provide protection 
from diabetes. 
T 
he  nonobese  diabetic  (NOD) 1  mouse  spontaneously 
develops autoimmune diabetes (1-4), and is considered 
an appropriate model for examining the etiology of human 
type I diabetes.  As in human diabetes,  the murine disease 
is associated with lymphocytic infiltration of pancreatic islets 
(insulitis) (1,  5),  the appearance of autoantibodies directed 
against 3  cell proteins (6-13), the T  cell-mediated destruc- 
tion of 3 cells (14-17),  and the presence of  both MHC-linked 
(18-24) and non-MHC-linked (25-30) disease susceptibility 
genes. 
As analyzed in an outcross with the C57BL/10SnJ strain, 
the development of diabetes in the NOD mouse is under poly- 
1 Abbreviation used in this  paper: NOD, nonobese diabetic. 
genic control (20).  At least  three non-MHC-linked genes, 
located on chromosomes 1, 3, and 11 (25, 26), as well as one 
or more genes in the MHC (18, 20-22) contribute to disease 
progression and onset. The MHC class II region has been 
implicated in disease susceptibility, with the NOD strain ex- 
pressing a unique I-A B chain (22) and no surface I-E mole- 
cules due to a lack of I-E ot chain production (18). Evidence 
supporting the involvement of NOD class II products in di- 
abetogenesis comes in part from studies using the cataract 
Shionogi (CTS) mouse. The CTS strain is identical to the 
NOD strain at the class II region of the MHC, but differs 
at the K and D class I loci (31). When two doses of the CTS 
MHC were expressed on the NOD background, the resulting 
congenic mice developed insulitis and diabetes (32). A second 
approach, using transgenic technology to express non-NOD 
class II products in NOD mice, has provided perhaps the 
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in diabetogenesis. In these studies, expression of I-E (33-36) 
and non-NOD  I-A transgenes (37, 38) in the NOD  strain 
provided a high degree of protection from insulitis and diabetes. 
Two groups have demonstrated that expression of I-E after 
introduction of an I-E ot  a transgene inhibits the development 
of insulitis and diabetes in NOD  mice (33-36).  Such com- 
plete protection from disease progression was not observed, 
however, in NOD.H-2F/,bl  mice (the NOD H.2e7 complex 
is K d I-A  n~  I-E  nnll Db;  the/'/-2  "b~ complex from the nono- 
bese nondiabetic [NON] strain is K n~  I-A  n~  I-E  n~  D b [31, 
39]);  although no NOD.H-2F/,bl  mice developed diabetes, 
one dose of I-E failed to prevent the development of mild 
insulitis in 37%  of animals,  and severe insulitis  in 16%  of 
animals  (40). 
To determine the extent of disease protection provided by 
the expression of I-E in NOD  mice, various I-E + and I-E- 
MHC haplotypes were bred onto the NOD background, and 
the resulting NOD MHC congenic animals crossed with the 
NOD  strain to produce the F~ generation.  Both I-E + and 
I-E-  F~ mice developed insulitis and diabetes, indicating that 
I-E expression in NOD mice is not in itself sufficient to pre- 
vent the development of diabetes. 
Materials and Methods 
Animals.  NOD/MrkTacfBR (NOD) mice were obtained from 
Taconic Farms (Germantown, NY). C57BL/10SnJ (B10), B10.D2 
(R107)/EgDvEg (B10.D2 [R107]), B10.A(5R)/SgSnJ (B10.A[5R]), 
B10.A(4R)/SgDvEg (B10.A[4R]),  B10.A(2R)/SgSnJ  (B10.A[2R]) 
and B10.BR/SgSnJ (B10.BR) mice were obtained from The  Jackson 
Laboratory (Bar Harbor, ME). Mice at Taconic Farms and Merck 
Research Laboratories were housed under sterile, specific pathogen- 
free conditions, and do not harbor any known viral, bacterial, or 
parasitic  pathogens. 
NOD  mice  were  outcrossed  to  the  B10,  B10.D2(R107), 
B10.A(5R), B10.A(4R), B10.A(2R), and B10.BR strains, and the 
progeny repetitively  backcrossed to the NOD strain. Breeders were 
selected on the basis of heterozygosity at the MHC, after detection 
of class I and II MHC products on PBMC using the mAbs listed 
below.  At the fifth (N6) generation, male and female MHC bet- 
erozygotes were intercrossed, and MHC homozygous progeny in- 
bred, in order to fix each MHC haplotype of the above strains on 
the NOD background. 
Unless otherwise specified, all experiments used female mice. 
Animals were tested biweekly for elevated urinary glucose using 
Tes-Tape (Eli Lilly and Co., Indianapolis,  IN), and classified as dia- 
betic after exhibiting glucose values of >t2+. 
MHC Typing.  Dissociated spleen cells or PBMC were incubated 
with one of the following FITC-conjugated mouse mAbs (Phar- 
Mingen, San Diego, CA): anti-K  a (SFI-I.1), anti-K  b (AF6-88.5), 
anti-K  k (AF3-12.1), anti-I-A b (AF6-120.1), anti-I-A  k (11-5.2), anti- 
I-A  k,r,f,~ (11-3.25), which is reactive with I-A  ~~  and I-A  k but not 
I-A  b, anti-I-E  a,k,p,~ (AMS-16),  and anti-D  a (AF4-62.4).  All mAbs 
were titrated and used at optimal concentrations. After incubation 
with mAbs at 4~  for 20 min, the cells were washed and then 
analyzed by flow cytometry on the FACS IV  |  or FACStar PLUS  | 
(Becton Dickinson & Co., Mountain View, CA). Propidium io- 
dide was  added to exclude dead ceils from the analysis. 
All strains  of mice were tested with the eight class I- or class 
II-specific mAbs listed above. Ceils from the NOD strain bound 
only the mAbs specific for K d and I-A  k'r'f's. Cells  from each pa- 
rental strain and its corresponding MHC congenic strain bound 
the following mAbs: B10 and NOD.H-2  b, anti-K  b and anti-I-Ab; 
B10.D2(R107) and NOD.H-2  ~7, anti-K  b, anti-I-A  b, and anti-Dd; 
B10.A(5R) and NOD.H-2  ~, anti-K  ~, anti-I-A  b, anti-I-E  d'k'p'r, and 
anti-Dd; B10.A(4R) and NOD.H-2  h4, anti-K  k, anti-I-A k, and anti- 
I-Ak'r'f's; B10.A(2R)  and NOD.H-2  h2, anti-K  k,  anti-I-A  k,  anti-1- 
A k'r'f's, and anti-I-Ea.k.p.r; and B10.BR and NOD.H-2  ~,  anti-K  k, 
anti-I-A  k, anti-I-A  ~,~,f,s, and anti-I-E  a,k,p,r. 
Histology.  Pancreata were fixed in 10% buffered formalin and 
processed  for paraffin  embedding.  Tissue sections  (5 /xm) were 
stained with hematoxylin and eosin and microscopically evaluated 
for the presence of mononuclear cell infiltration. Two noncontig- 
uous sections of each pancreas (45-50/zm between sections) were 
examined.  Histology scores  used  were:  normal,  no infiltrating 
mononuclear cells observed  in the pancreas;  PV/PD, infiltrating 
cells observed only in perivascular  and/or periductal locations of 
the pancreas;  mild insulitis,  mononuclear cell infiltration of islet 
tissue is limited to less than half of the islets in the two tissue sec- 
tions; and extensive insulitis, mononuclear cells permeate most islets 
and fl cell necrosis is seen. 
Cyclophosphamide Treatment.  Lyophilized cydophosphamide (Cy- 
toxan; Mead Johnson Oncology Products, Evansville, IN) was pre- 
pared immediately before use by adding sterile distilled  water to 
give a final concentration of 20 mg/ml. Nondiabetic mice received 
200 mg/kg by intraperitoneal injection on days 0 and 14, and were 
monitored for diabetes  up to 28 d after the first injection. 
Preparation  and Analysis of  Bone Marrow Chimeras.  Bone marrow 
cells were harvested from 7-wk-old NOD and 7-11-wk-old (NOD 
x  NOD.H-2~)Ft and (NOD  x  NOD.H-IS)F1 female donors. To 
eliminate mature T  cells, the bone marrow cells were incubated 
at 4~  for 30 min with a mixture of the following mAbs: anti- 
Thy-l.2 (HO-D-4) (41) (TIB 99; American Type Culture Collec- 
tion, Rockville, MD), anti-Lyt-l.2 (C3PO.13) (42), and anti-Lyt-2 
(3.155) (43) (TIB 211; American Type Culture Collection). The 
cells were then incubated with absorbed guinea pig complement 
at 37~  for 30 min. 6-wk-old NOD and 7-14-wk-old (NOD  x 
NOD.H-2~)FI and (NOD  x  NOD.H-2~s)F1  female ~cipients were 
irradiated with  1,000  tad  from a  13VCs source (Gammacell 40; 
Atomic Energy of Canada, Ltd., Ottawa, Ontario) and injected 
intravenously with 10-20  x  106 bone marrow cells. Chimeras are 
designated as bone marrow donor ~  irradiated recipient. 
Chimeras were monitored for the development of diabetes for 
6-7 mo after bone marrow reconstitution. To detect the percentage 
of contaminating cells originating from irradiated recipients, spleen 
cells from diabetic chimeras were typed with the class I-specific 
mAbs  described above.  In  a  group of 13  NOD  ~  (NOD  x 
NOD.H-2~)Fx  chimeras  typed,  the  percentage  of residual  K k- 
positive (NOD  x  NOD.H-21)F1 cells ranged from 1.9 to 5.2%, 
with a mean of 3.7%.  In a group of three NOD -- (NOD  x 
NOD.H-2~S)FI chimeras typed, the percentage Kb-positive (NOD 
x  NOD.H-2~S)F1 cells ranged from 0.3 to 0.7%, with a mean of 
0.5%. Thus, in all chimeric mice tested, >--95% of the spleen cells 
expressed  the class I and II MHC products of the bone marrow 
donor. 
Results and Discussion 
Establishment  of 1-E +  and  l-E-  NOD  MHC  Congenic 
Strains.  To establish the NOD.H-2 b, NOD.H-,~ 7, NOD.H- 
I s, NOD.H-2 .4, NOD.H-2 h2, and NOD.H-2 k strains, NOD 
mice were outcrossed to B10 (H-2~),  B10.D2(R107)  (H-2~7), 
B10.A(5R) (H-2~s), B10.A(4R) (H-2h*),  B10.A(2tL) (H-2h2), 
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MHC product 
K  I-A  I-E  D 
ct  ~  B  c~  Cyclophosphamide  No. Diabetic/no. observed (%) 
NOD  d  d nod  nod -  b  No  41/50 (82) 
Yes  8/9  (89) 
NOD.H-2  b  b  b  b  b  -  b  No  0/21  (0) 
Yes  0/11  (0) 
NOD.H-2 i7  b  b  b  b  -  d  No  0/40 (0) 
Yes  0/14 (0) 
NOD.H-2 ~s  b  b  b  b  k  d  No  0/39 (0) 
Yes  0/13 (0) 
NOD.H-2  h4  k  k  k  b  -  b  No  0/54 (0) 
Yes  0/11  (0) 
NOD.H-2 h2  k  k  k  k  k  b  No  0/38 (0) 
Yes  0/13 (0) 
NOD.H-2  ~  k  k  k  k  k  k  No  0/31  (0) 
Yes  0/4  (0) 
All mice represented in this table were females. NOD and NOD MHC congenic mice were monitored for spontaneous diabetes for 7 and 5-13 
too, respectively.  The groups indicated received  200 mg/kg of  cyclophosphamide  intraperitoneally  on days 0 and 14, and were monitored  for diabetes 
up to 28 d after the first injection. NOD and NOD MHC congenic  mice were treated with cyclophosphamide  at 6 and ~>5 mo of age, respectively, 
and were normoglycemic  at the initiation of treatment. 
and B10.BR (1-1-2  ~) mice, respectively, and repetitive back- 
crosses to the NOD were performed using progeny expressing 
the MHC haplotypes of the strains above. To fix these MHC 
haplotypes on the NOD background, mice at the N6 gener- 
ation were intercrossed, and the resulting congenic strains 
(Table 1) maintained by brother-sister mating. 
Examination of female NOD MHC homozygotes at the 
N6F1 generation revealed a 74% incidence of diabetes by 5-7 
mo of age (Table 2), consistent with the 65-82% incidence 
observed in 5-7-mo-old female NOD mice in our colony (Table 
1) (25). This suggests that the non-MHC-linked diabetogenic 
genes are fixed for the NOD allele in each of the congenic 
strains.  Thus, any influence on the diabetogenic process in 
NOD MHC congenic mice, as compared with the NOD 
strain,  is the result of the non-NOD MHC. 
Incidence  of lnsulitis and Diabetes in NOD  MHC  Congenic 
Strains.  In the NOD mouse, the autoimmune destruction 
of pancreatic/~ cells begins as a perivascular and periductal 
accumulation of lymphocytes (PV/PD), evident by 3 wk of 
age.  Lymphocytic infiltration of the islets  can be observed 
as early as 4 wk of age,  and by 3 too, overt diabetes begins 
to occur (1-4). In our colony, 82% of females (Table 1) (25) 
and 45% of males (n  -- 49) develop diabetes by 7 mo of age, 
and nearly all females and males develop insulitis  (11, 44). 
Treatment with cyclophosphamide, an agent that increases 
the rapidity and incidence of diabetes in the NOD mouse 
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(45), causes 89% of female (Table 1) (11) and 73% of male 
(11) 6-mo-old nondiabetic NOD mice to develop diabetes. 
Cyclophosphamide fails to induce insulitis or diabetes in non- 
diabetic strains of  mice (44-46), suggesting that cydophospha- 
mide induces diabetes only if a suf~cient degree of insulitis 
has developed before treatment. 
Table 2.  Incidence of Spontaneous Diabetes in N6FI Mice 
NOD.H.2~7/.r 7 NOD.H.2~7/non-g7 NOD.H.2~on.~7/non-g7 
NOD.H-2  b  7/7  0/5  0/9 
NOD.H-2 i7  1/3  0/13  0/9 
NOD.H-2/s  6/8  0/10  0/10 
NOD.H-2 h4  2/5  0/13  0/6 
NOD.H-2 h2  6/8  0/5  0/2 
NOD.H-2  ~  3/3  0/15  0/6 
Total  25/34 (74%)  0/61  (0%)  0/42 (0%) 
MHC heterozygous  mice at the fifth (N6) backcross generation were in- 
tercrossed and the MHC type of the resulting female  progeny  was deter- 
mined. Intercross progeny were monitored for diabetes for 5-7 mo. Examination of the NOD MHC congenic strains showed 
that each of the strains developed perivascular and periductal 
lymphocytic infiltration spontaneously by 7-10 mo of age 
(Table 3).  Mice ranging from 5 to 13 mo of age that were 
treated with cyclophosphamide exhibited perivascular  and 
periductal infiltrates as well. Four of the six congenic strains 
failed to develop insulitis (Table 3) or diabetes  (Table 1), ei- 
ther spontaneously or after cyclophosphamide treatment. In 
contrast, both I-E + NOD.H-2 h2 mice and I-E- NOD.H-2  h4 
mice developed insutitis (Table 3 and Fig. 1). These mice failed, 
however,  to develop diabetes,  either spontaneously or after 
treatment with cyclophosphamide (Table 1). 
The importance of the MHC in the development of dia- 
betes is supported by the observation that expression  of two 
doses of a non-NOD MHC on the NOD background pro- 
vides complete protection from disease. The fact that both 
the I-E + NOD.H-2  h2 and the I-E-  NOD.H-2  h* strains  de- 
veloped insulitis suggests that I-E does not play a critical role 
in this process. It is of interest, however, that both of these 
strains  express  I-A  k  and  D b  (Table  1).  Given  that  the 
NOD.H-2 k strain, which expresses I-A  k but not D b, and the 
NOD.H-2 b strain, which expresses D b but not I-A  k, fail to 
develop insulitis, it is possible that the combination of I-A  k 
and D b (or genes  closely linked to these loci) confers sus- 
ceptibility to lymphocytic infiltration of the islets, but not 
to the development of diabetes. 
Incidence  of lnsulitis and Diabetes in FI Mice Not Expressing 
I-E.  Each NOD MHC congenic strain was crossed with 
the NOD  strain to produce the F1 generation; thus, in F1 
mice, one dose of the NOD MHC and one dose of a non- 
NOD MHC is expressed on the NOD background. Exami- 
nation of the pancreata of nondiabetic female mice within 
the three I-E- F1 strains revealed the presence of perivascular 
and periductal infiltrates in both untreated (age,  6-10 mo) 
and cydophosphamide-treated (age, 5-12 mo) mice (Table 4). 
The (NOD  x  NOD.H-2h4)F1 and (NOD  x  NOD.H-2b)F1 
Table 3.  Pancreatic Histology  of Nondiabetic NOD MHC Congenic Mice 
Histology Score (%) 
Mild  Extensive 
Age  No. observed  Cyclophosphamide  Normal  PV/PD  insulitis  insulitis 
NOD.H-2  ~ 
trio 
7-10  10  No  3 (30)  7 (70)  0 (0)  0 (0) 
6-11  11  Yes  6 (55)  5 (45)  0 (0)  0 (0) 
NOD ./-/-2  ~7 
9  15  No  9 (60)  6 (40)  0 (0)  0 (0) 
5-11  14  Yes  7 (50)  7 (50)  0 (0)  0 (0) 
NOD.H-s  s 
7-10  13  No  10 (77)  3 (23)  0 (0)  0 (0) 
5-9  13  Yes  9 (69)  4 (31)  0 (0)  0 (0) 
NOD.l-l-2  h4 
8-10  17  No  4 (24)  8 (47)  3 (17)  2 (12) 
5-13  11  Yes  3 (30)  6 (60)  1 (10)  0 (0) 
NOD.H-2  h2 
9  15  No  0 (0)  10 (67)  4 (27)  1 (6) 
10-12  13  Yes  4 (31)  9 (69)  0 (0)  0 (0) 
NOD.l-l-2  ~ 
7-8  21  No  6 (29)  15 (71)  0 (0)  0 (0) 
6-7  4  Yes  3 (75)  1 (25)  0 (0)  0 (0) 
All mice represented in this table were nondiabetic  females.  The groups indicated  received  200 mg/kg of cyclophosphamide  intraperitoneally  28 and 
14 d before  histological  examination.  Two noncontiguous  sections of pancreas were stained  with hematoxylin  and eosin  and microscopically  evaluated 
for the presence of mononuclear cell infiltration. Histology  scores used were: normal, no infiltrating  mononuclear  cells observed in the pancreas; 
PV/PD, infiltrating  cells observed only  in perivascular and/or periductal locations of the pancreas; mild insulitis, mononuclear  cell infiltration  of 
islet tissue is limited to less than half of the islets in the two tissue sections; extensive  insulitis, mononuclear  cells permeate most islets and B cell 
necrosis is seen. 
796  I-E + Nonobese Diabetic Mice Develop Insulitis and Diabetes Figure  1.  Pancreatic histology of a female NOD.H-2  h2 mouse, showing extensive insulitis. Hematoxylin and eosin (x200). 
Table  4,  Pancreatic  Histology and l~'abetes Incidence in I-E-  F~ Mice 
Pancreatic histology of nondiabetic  mice 
Histology score (%)  Diabetes incidence 
Cyclophosphamide  Mild  Extensive  No.  diabetic/ 
treatment  Age  No.  observed  Normal  PV/PD  insulitis  insulitis  Age  no.  observed (%) 
mO  mO 
(NOD  x  NOD.H-2h4)F1 
No  7-10  15  2  (13)  4  (27)  2  (13)  7  (47)  5-11  0/37  (0) 
Yes  5-11  11  4  (37)  3  (27)  0  (0)  4  (36)  5-11  11/22  (50) 
(NOD  x  NOD.H.2~ 
No  8  3  1  (33)  2  (67)  0  (0)  0  (0)  5-8  0/17  (0) 
Yes  5-7  11  7  (64)  4  (36)  0  (0)  0  (0)  5-7  3/t4  (21) 
No*  5-6  15  10  (66)  1 (7)  4  (27)  0  (0) 
(NOD  x  NOD.H-2b)Ft 
No  6-8  30  1  (3)  13  (43)  5  (17)  11  (37)  6-9  0/56  (0) 
Yes  5-12  33  9  (27)  16  (49)  4  (12)  4  (12)  6-9  13/56  (23) 
Pancreatic histology and diabetes incidences were performed as described for Tables 3 and 1, respectively. 
* Pancreata from nondiabetic male mice were examined for the presence of mononuclear cell infiltration.  All other  mice represented in this table 
were females. 
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Pancreatic histology of nondiabetic mice 
Cyclophosphamide 
treatment  Age  No. observed  Normal 
Histology score (%)  Diabetes incidence 
Mild  Extensive  No. diabetic/ 
PV/PD  insulitis  insulitis  Age  no.  observed (%) 






















ND  5-7  0/118 (0) 
10  7 (70)  3 (30)  0 (0)  0 (0)  5-7  0/10 (0) 
31  11 (36)  19 (61)  0 (0)  1 (3)  10-17  3/108  (3) 
32  15 (47)  16 (50)  0 (0)  1 (3)  10-17  4/72 (6) 
15  5 (33)  6 (40)  3 (20)  1 (7)  6-7  0/93 (0) 
11  1 (9)  6  (55)  2  (18)  2  (18)  6-7  4/15  (27) 
13  0 (0)  5 (38)  5 (38)  3 (24)  9-17  3/62 (5) 
29  4 (14)  14 (48)  2 (7)  9 (31)  11-17  2/43  (5) 
7-8  10  3  (30)  2  (20)  1 (10)  4  (40)  6-8  0/15 (0) 
6-7  4  0 (0)  3 (75)  0 (0)  1 (25)  6-7  1/5 (20) 
Pancreatic histology and diabetes incidences were performed as described for Tables 3 and 1, respectively. Spontaneous diabetes in the (NOD  x 
NOD.H-2iS)F1 mice occurred at 10, 11, and 13 mo of age, and in the (NOD  x  NOD.H-2t')F1 mice at 12, 14, and 15 mo of age. 
strains displayed insulitis under both conditions as well. Due 
to  the  small  number  of female  (NOD  x  NOD.H-2~'7)F1 
mice observed, pancreata from 15 untreated male (NOD  x 
NOD.H-2a)F, mice were also examined.  4 of the 15 males 
(27%)  exhibited mild insulitis,  indicating  that  the (NOD 
x  NOD.H-2a)F1 strain is susceptible to the development of 
insulitis  as well. 
Although  no  (NOD  x  NOD.H-2h4)F,,  (NOD  x 
NOD.H-2a)Fh  or (NOD  x  NOD.H-2b)F1 mice spontane- 
ously developed diabetes by 5-11 mo of age, cyclophospha- 
mide induced disease in each of the three strains (Table 4). 
Examination of the pancreata of these diabetic mice revealed 
extensive insulitis,  consistent with the onset of diabetes. 
The  development  of insulitis  and  diabetes  in  I-E-  H- 
2g  7/n~  mice has been previously observed. In female (NOD 
x  SWIL/J)F1  x  NOD  MHC  heterozygotes  (47)  and 
(NOD  x  B10)F1  x  NOD N3-8 MHC heterozygotes (48), 
insulitis and a low incidence of spontaneous diabetes devel- 
oped, consistent with our finding in this study that a single 
dose of the NOD MHC is sufficient to mediate insulitis and 
cyclophosphamide-induced diabetes. 
Incidence of lnsulitis and Diabetes in F1 Mice Expressing I-E. 
I-E + F1 mice were aged 5-8 or 9-17 too, and analyzed for 
the development of perivascular and periductal infiltration, 
insulitis,  and diabetes. Perivascular and periductal infiltrates 
were observed in  each  age  group  of untreated  and cyclo- 
phosphamide-treated  (NOD  x  NOD.H-~'S)F1,  (NOD 
x  NOD.H-2k)F,, and (NOD  x  NOD.H-2~F1 mice (Table 
5). Insulitis was present in untreated and cyclophosphamide- 
treated 6-8-mo-old (NOD  x  NOD.H-2~)F1 and (NOD  x 
NOD.  H-2hZ)F1 mice  (Fig.  2),  as well as in  9-17-mo-old 
(NOD  x  NOD.H-2~)F1 mice.  Cyclophosphamide-treated 
5-7-too-old (NOD  x  NOD.H-2~S)F1 mice did not exhibit 
insulitis, although a small percentage of mice aged 10-17 mo 
did  display insulitis  with  and  without  cyclophosphamide 
treatment. 
While 5-8-mo-old (NOD  ￿  NOD.H-2~S)Ft, (NOD  x 
NOD.H-2~)F1 and (NOD  x  NOD.H-2h2)F1  mice failed to 
develop diabetes spontaneously,  treatment with cyclophospha- 
mide induced diabetes in both the (NOD  x  NOD.H-2~)Ft 
and (NOD  x  NOD.H.2h2)F1 strains (Table 5). In addition, 
a small percentage of (NOD  x  NOD.H-2/S)F1 and (NOD 
x  NOD.H-2k)F,  mice  aged  9-17  mo  developed diabetes 
spontaneously, as well as after cyclophosphamide treatment. 
Examination  of the pancreata of these mice revealed  exten- 
sive insulitis,  consistent with  the onset of diabetes. 
This is the first report of I-E + NOD mice developing di- 
abetes. Insulitis, but no diabetes, was previously observed in 
I-E +  NOD.H.2g 7/"~l mice  (40).  It  is  of interest  that  the 
NOD.H-2g 7/n~I mice were aged to 10 mo; by this age only 
one of the six spontaneously diabetic I-E + F1 mice in our 
study had developed disease (Table 5). Thus, the kinetics of 
disease onset may be an important  consideration  in deter- 
mining  the role of I-E in diabetogenesis. 
798  I-E + Nonobese Diabetic Mice Develop Insulitis and Diabetes Figure 2.  Pancreatic histology of female (NOD  x  NOD.H-2~)F1 (A) and (NOD  x  NOD.H-2~OF1  (B) mice, showing extensive insulitis. Hema- 
toxylin and eosin (x 125). In contrast to the results detailed above, expression of an 
I-E o~  a transgene in NOD mice was found to provide com- 
plete  protection  from  diabetes  (33-36).  In  these  studies, 
C57BL/6  mice expressing an I-E cra transgene were out- 
crossed to the NOD strain, and I-E + progeny repetitively 
backcrossed to the NOD (33, 34),  or an I-E c~  d transgene 
was introduced directly into NOD mice (34-36).  In both 
cases, I-E expression protected mice from the development 
of insulitis  and  diabetes,  even  after  treatment  with  cy- 
clophosphamide (35, 36). Interestingly, expression of an I-E 
ot  k transgene in second backcross (to NOD) progeny pro- 
vided incomplete protection from disease progression, with 
mild insulitis, but no diabetes, developing in 1 of 18 mice 
(49).  One possible interpretation of these results is that I-E 
otk~  ~~ is more permissive for disease development than I-E 
otd3  "~  It should be noted, however, that the sequences of 
I-E c~  k and I-E ot  a are identical in the peptide binding c~1 
domain, and differ by only three amino acids in the or2 do- 
main (50). Thus, other experimental differences may account 
for the variability in disease protection provided by the ex- 
pression of an I-E ot transgene. 
One explanation for the differing degrees of protection ob- 
served in I-E + NOD mice is the variable environments in 
which the mice are maintained. It is well established that 
environmental factors affect the incidence of diabetes in NOD 
colonies (51-53).  In addition, infection with viruses, such 
as mouse hepatitis virus,  affects  the diabetogenic process, 
significantly decreasing the incidence of disease (54).  Such 
environmental influences may be of even greater consequence 
when acting upon less diabetogenic strains,  such as NOD 
mice that express non-NOD MHC products. For instance, 
in our high incidence colony, >95%  of NOD mice devel- 
oped insulitis as compared with 50% of (NOD  x  NOD.H- 
2~)F,  mice,  with  insulitis  in  the  latter  developing  at  a 
significantly slower rate (11). Similarly, the incidence of dia- 
betes in female animals decreased from 82%  in the NOD 
strain to 3%  in the (NOD  x  NOD.H-2~)F~  strain.  Had 
these animals been maintained in a lower incidence colony, 
it is possible that the prevalence of insulitis and diabetes in 
(NOD  x  NOD.H-2~)F, mice would have been decreased to 
an extent that little insulitis and no diabetes could be de- 
tected. Thus, as a result of environmental influences, quan- 
titative variability among mice maintained in different en- 
vironments may appear instead as qualitative differences. The 
fact that the effects of expressing I-E in diabetogenic mice 
maintained in different environments has ranged from com- 
plete protection from insulitis and diabetes (33-36), to mild 
insulitis in a low percentage of mice (49), to more severe in- 
sulitis in a higher percentage of mice (40),  to the develop- 
ment of insulitis as well as spontaneous and cyciophosphamide- 
induced diabetes (Table 5) suggests that environmental factors 
may influence diabetogenesis in I-E + NOD mice. 
Alternatively, or in addition to environmental influences, 
the variability in disease protection observed in I-E § NOD 
mice may be the result of the different non-NOD MHC- 
linked genes present in the mice, and thus a consequence of 
the approach used to express I-E on the NOD background. 
While the transgenic NOD mice expressed either I-E cga~  ~ 
(33-36)  or  I-E  c~kB  n~  (49),  the NOD.H-2g 7/"bI mice ex- 
pressed both I-E ot~~  n~  and I-E o~n~  n~  (40).  Similarly, 
our I-E + F1 strains expressed two I-E otfl pairs, with (NOD 
x  NOD.H-2iS)F1 mice expressing I-E ot~fl  b and I-E otk~  n~ 
and (NOD  x  NOD.H-2~)F1 mice and (NOD  x  NOD.H- 
2k)F1 mice expressing I-E otk~  k and I-E c~k~. Thus, trans- 
genic technology produced only one I-E molecule of either 
the c~dfl  u~  or C~k~  ~~  type, while conventional genetic ap- 
proaches produced two I-E types in each animal. In the studies 
presented here, I-E otkfl  b or otk~  k, as well as I-E ak~  ~~  were 
expressed in each I-E + mouse. Whether such differences are 
significant in determining disease susceptibility remains to 
be determined. It is possible that I-E otd'~  ~  is more pro- 
tective than I-E akfl  b or akfl  k, and that conventional genetic 
approaches result in reduced levels of I-E c~.k~  ~  due to the 
concomitant expression of I-E c~k~  b or otkB  k, thereby ren- 
dering animals more susceptible to the development of dia- 
betes. It is only when transgenic technology and conventional 
genetic approaches are used under the same environmental 
conditions that the roles of genetics versus the environment 
in I-E protection can be delineated. 
Each Fa strain in our study was provided some degree of 
protection through the expression of a single dose of a non- 
NOD  MHC.  It should be noted that while subtle differ- 
ences in the level of protection were apparent amongst the 
strains,  this variability was not significant. Of interest is the 
fact that the I-E + F1 strains were no more protected from 
disease than the I-E- F1 strains.  Age-related groups of I-E + 
and I-E- F1 mice exhibited similar incidences of perivascular 
and periductal infiltration, insulitis, and eventually sponta- 
neous or cyclophosphamide-induced diabetes. Thus, the pro- 
tective effect provided by one dose of a non-NOD MHC was 
not augmented by the expression of I-E. 
A possible explanation for this observation is that I-E and 
non-NOD I-A provide protection from diabetes via the same 
mechanism, and that maximal protection by dass II mole- 
cules can be achieved through the expression of either I-E 
or I-A alone. Since each F: strain expressed a non-NOD I-A, 
the concomitant expression of I-E in the (NOD  x  NOD.H- 
(NOD  ￿  NOD.H-2 )F1, and (NOD  ￿  NOD.U- 
2'2)F1 strains did not increase the degree of protection in 
these mice as compared with the I-E-  F~ strains.  In accor- 
dance with this theory, the expression of an I-A  k transgene 
in NOD mice has been found to markedly reduce insulitis 
(37, 38), and completely prevent the development of diabetes 
(37). 
Incidence of Diabetes in Bone Marrow Chimeras.  To deter- 
mine the diabetogenic potential of NOD hematopoietic stem 
cells educated in an I-E + F1 environment, lethally irradiated 
(NOD  x  NOD.H-2~)F1 and (NOD  x  NOD.H-2a)F1 mice 
were reconstituted with NOD bone marrow. Use of irradi- 
ated NOD mice as bone marrow recipients resulted in an 
83% incidence of diabetes (Table 6), nearly identical to the 
incidence seen in unmanipulated NOD mice (Table 1). This 
indicates that the experimental procedure itself does not pre- 
vent disease development in chimeric mice. In addition, (NOD 
800  I-E+ Nonobese Diabetic Mice Develop Insulitis and Diabetes Table  6.  Incidence  of Spontaneous Diabetes in Chimeric Mice 
Donor -* Recipient 
No. diabetic/  Mean age of 
no.  observed (%)  onset  _+ SD 
NOD "~ NOD 
NOD "* (NOD  x  NOD.H-2~)F1 
NOD ~  (NOD  x  NOD.H-10Ft 
(NOD  x  NOD.H-2k)F, ~  (NOD  x  NOD.H-2k)F, 
(NOD  x  NOD.H-2~S)F, ~  (NOD  x  NOD.H-2~S)F~ 
d 
5/6 (83)  124  _+  8 
20/30  (61)  131  +  19 
4/9 (44)  136  _+  33 
1/18  (6)  126 
0/9 (0) 
All mice represented in this table were females. Chimeras are designated as bone marrow donor ~  irradiated recipient. Kecipients  were 7-11 wk 
of age at the time of bone marrow reconstitution,  and were monitored  for diabetes for 6-7 mo after chimera construction. The mean age of onset 
represents the number of days between chimera construction and onset of diabetes. 
x  NOD.H-2k)F1 -~ (NOD  x  NOD.H-2k)Ft and (NOD  x 
NOD.H-2~S)F1 ~  (NOD  x  NOD.H-2~  bone marrow 
chimeras showed low incidences of diabetes (Table 6), similar 
to  those of unmanipulated (NOD  x  NOD.H-2~)F1  and 
(NOD  x  NOD.H-2~S)F1 mice (Table 5).  Thus, irradiation 
and bone marrow reconstitution does not artificially induce 
diabetes. 
Reconstitution of irradiated (NOD  x  NOD.H-2k)F1  and 
(NOD  x  NOD.H-IS)F1  mice with NOD  bone marrow 
resulted in diabetes incidences of 61 and 44%, respectively, 
by 6-7 mo after chimera construction (Table 6). In compar- 
ison, unmanipulated (NOD  x  NOD.H-2k)F1  and (NOD 
x  NOD.H-2~S)F1 mice failed to develop  spontaneous dia- 
betes by 5-7 mo of age, and showed incidences of 5 and 3%, 
respectively, by 9-17 mo of age (Table 5). Thus, NOD bone 
marrow-derived cells retain their ability to induce a high in- 
cidence of diabetes in (NOD  x  NOD.H-2k)F1  and (NOD 
x  NOD.H-~'S)F1 mice, despite being educated in the pres- 
ence of an I-E + non-NOD MHC. 
These results indicate that the high degree of disease pro- 
tection provided by one dose of a non-NOD MHC requires 
expression of the non-NOD MHC products in bone marrow- 
derived cells; expression of these products in the thymus alone 
fails to provide protection from diabetes.  A similar conclu- 
sion was reached by B6hme et al. (49), who found that the 
incidence of insulitis in  I-E +  NOD  transgenic mice was 
greatly reduced when I-E was expressed in both the thymus 
and in peripheral lymphoid cells, but not when I-E was ex- 
pressed in the thymus alone.  A possible explanation for the 
importance of peripheral MHC expression in disease protec- 
tion is that non-NOD class II molecules reduce or prevent 
binding of diabetogenic peptides to the NOD class II mole- 
cule, resulting in a reduction or lack of autoantigen presenta- 
tion to the immune system (55, 56). Alternatively, immune 
responses restricted by non-NOD class II products may ex- 
pand the islet-reactive  Th2 population, which in turn could 
downregulate 3  cell-specific  immune destruction (57). 
In summary, the studies presented here indicate that I-E 
expression in NOD mice is not sufficient to prevent insulitis 
or diabetes.  The expression  of two doses  of an I-E + or I- 
E- non-NOD MHC on the NOD background can be per- 
missive for insulitis, although diabetes fails to develop in the 
absence of the NOD MHC. NOD mice expressing one dose 
of an I-E + or I-E-  non-NOD MHC and one dose of the 
NOD MHC exhibit a high degree of disease protection, al- 
though insulitis and diabetes  do develop in a percentage of 
these animals.  Interestingly, I-E + MHC heterozygous mice 
are no more protected from diabetes  than are I-E-  MHC 
heterozygotes. Construction of bone marrow chimeras indi- 
cates  that expression  of non-NOD  MHC products in the 
thymus, in the absence of expression  in bone marrow-de- 
rived cells, fails to provide protection from diabetes. 
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